Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DNG003
MIFTS: 66

Dengue Disease

Categories: Rare diseases, Infectious diseases, Genetic diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dengue Disease

About this section

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 37 12 14
Dengue Fever 12 72 49 3 69
Dengue 51 40 41
Dengue Shock Syndrome 49 69
Df 49 3
Philippine Hemorrhagic Fever 49
Singapore Hemorrhagic Fever 49
Dengue Hemorrhagic Fever 49
Dengue Virus Infection 49
Thai Hemorrhagic Fever 49
Hemorrhagic Dengue 49
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 69

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Genetic diseases
See all MalaCards categories (disease lists)
ICD10: 32


Sources

Summaries for Dengue Disease

About this section
NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 99828Disease definitionDengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).EpidemiologyDF is found in the tropics worldwide, especially in Southeast Asia, the Pacific region, and the Americas, with 40% of the global population at risk. An estimated 50 to 100 million cases of DF, 500,000 hospitalizations, and 20,000 deaths occur yearly worldwide.Clinical descriptionThe vast majority of dengue virus infections result in DF, which is characterized by sudden onset of fever, malaise, headache (classically retro-orbital), and myalgia/arthralgia, often followed soon after by a petechial rash, which may be pruritic. In most cases, symptoms will resolve within 7 days without further complications. However, in a small minority of patients, a brief period of deffervescence is followed by worsening abdominal symptoms (pain, nausea, vomiting, diarrhea), thrombocytopenia, hemorrhage (DHF: epistaxis, bleeding gums, gastrointestinal bleeding) and a capillary leak syndrome (DSS: hemoconcentration, hypoalbuminemia, pleural effusion, shock). DHF/DSS are seen most often in children under the age of 15 years. Risk is greater with secondary heterologous infection by one of the four dengue virus serotypes, but severe disease may be seen with first infections.EtiologyOver 25 different viruses cause viral hemorrhagic fever. Dengue virus belongs to the Flaviviridae family, genus Flavivirus. Four distinct serotypes, with significant strain variation, are recognized. Dengue viruses are maintained in humans and transmitted between them by the bite of infected mosquitoes, most commonly Aedes aegypti but also Aedes albopictus). Person-to-person transmission has not been reported.Diagnostic methodsCommon diagnostic modalities include serologic testing by enzyme linked immunosorbent assay (ELISA) and reverse transcriptionpolymerase chain reaction (RT-PCR). Virus isolation may also be performed in specialized laboratories. The viremic phase of DF/DHF is usually brief (first 3-5 days of illness), after which time detection of anti-dengue IgM antibodies, which appear as early as 2-4 days after disease onset, is the mainstay. Numerous commercial ELISA assays are available with varying degrees of sensitivity and specificity.Differential diagnosisDF is difficult to distinguish from a host of other febrile illnesses such as malaria and typhoid fever (see these terms), especially early in the course of disease before the rash appears. For DHF/DSS, other viral hemorrhagic fevers, leptospirosis, rickettsial infection (see these terms) and meningococcemia need to be excluded.Management and treatmentAs there is presently no antiviral drug available for DF/DHF, treatment is supportive, following the guidelines for treatment of severe septicemia. Insecticide-treated bed nets, room screens and elimination of larval development sites should be used in open-air settings to prevent further transmission.PrognosisCase-fatality rates for DF are less than 1% but may rise to as high as 40% in DHF/DSS, largely dependent upon whether access to advanced medical care exists. Children and persons with underlying chronic diseases such as diabetes, heart disease, and asthma are at increased risk. The most severe phase of disease usually lasts only a few days and survivors generally have no lasting sequelae.Visit the Orphanet disease page for more resources. Last updated: 12/1/2012

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue hemorrhagic fever and dengue shock syndrome, and has symptoms including fever, severe headache and severe pain behind the eyes. An important gene associated with Dengue Disease is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are hematopoietic system and immune system

MedlinePlus : 40 Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows NIH: National Institute of Allergy and Infectious Diseases

CDC : 3 With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus and the most effective protective measures are those that avoid mosquito bites. When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

Disease Ontology : 12 A viral infectious disease that results_in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

Wikipedia : 72 Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Sources

Related Diseases for Dengue Disease

About this section

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 dengue hemorrhagic fever 10.9
2 dengue shock syndrome 10.9
3 asymptomatic dengue 10.9
4 lymphocytic vasculitis 10.5 ICAM1 VCAM1
5 immunoglobulin g deficiency 10.5 CD40LG MBL2
6 heterophyiasis 10.4 CD40LG ICAM1
7 acquired thrombocytopenia 10.4 IL11 THPO
8 cortical thymoma 10.4 ICAM1 VCAM1
9 mooren's ulcer 10.4 ICAM1 VCAM1
10 trichostrongyloidiasis 10.4 CD40LG PIK3C2A
11 coccidioidomycosis 10.4 CD40LG MBL2
12 african tick-bite fever 10.3 CCL5 CD40LG
13 ornithosis 10.3 CD40LG PIK3C2A
14 secondary syphilis 10.3 CD209 CD40LG
15 kyasanur forest disease 10.3 CD40LG RAF1
16 thrombocytopenia due to platelet alloimmunization 10.3 CD40LG THPO
17 henoch-schoenlein purpura 10.3 CD40LG ICAM1 VCAM1
18 subendocardial myocardial infarction 10.3 ICAM1 VCAM1
19 oral lichen planus 10.3 CCL5 ICAM1 VCAM1
20 autoinflammation, lipodystrophy, and dermatosis syndrome 10.3 CCL5 ICAM1 VCAM1
21 actinic prurigo 10.3 ICAM1 VCAM1
22 trypanosomiasis 10.3 CCL5 ICAM1 VCAM1
23 severe acute respiratory syndrome 10.3 CCL5 CD209 CD40LG
24 vasculitis 10.2 CD40LG ICAM1 VCAM1
25 noonan syndrome with multiple lentigines 10.2 PTPN11 RAF1
26 idiopathic neutropenia 10.2 CCL5 CD40LG THPO
27 respiratory system disease 10.2 CCL5 CD40LG ICAM1
28 dermatomyositis 10.2 ICAM1 PIK3C2A VCAM1
29 rhinitis 10.2 CCL5 ICAM1 VCAM1
30 demyelinating disease 10.2 CCL5 CD40LG ICAM1
31 glomerulonephritis 10.2 CD40LG ICAM1 VCAM1
32 viral infectious disease 10.2 CCL5 CD209 CD40LG
33 shwartzman phenomenon 10.1 FCGR1A ICAM1 VCAM1
34 murray valley encephalitis 10.1 CD40LG RAF1
35 chylothorax, congenital 10.1 PTPN11 VCAM1
36 splenic disease 10.1 CD40LG THPO
37 pneumonia 10.0 CCL5 CD40LG MBL2 PIK3C2A
38 chronic eosinophilic pneumonia 9.9 CCL5 ICAM1
39 dengue virus 9.9
40 rheumatoid arthritis 9.8 CCL5 CD40LG ICAM1 IL11 VCAM1
41 asthma 9.7 CCL5 CD40LG ICAM1 IL11 VCAM1
42 endotheliitis 9.7
43 human immunodeficiency virus type 1 9.7 CCL5 CD209 FCGR1A RAF1
44 cerebral hemorrhage 9.7
45 thrombocytopenia 9.6
46 hemorrhagic fever 9.6
47 systemic lupus erythematosus 9.3 CCL5 CD40LG FCGR1A ICAM1 MBL2 SULT1A3

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease
Sources

Symptoms & Phenotypes for Dengue Disease

About this section

Symptoms:

12
  • • fever
  • • severe headache
  • • severe pain behind the eyes
  • • joint pain
  • • muscle
  • • rash
  • • mild bleeding

Human phenotypes related to Dengue Disease:

31 (show all 22)
# Description HPO Frequency HPO Source Accession
1 gingival bleeding 31 occasional (7.5%) HP:0000225
2 epistaxis 31 occasional (7.5%) HP:0000421
3 petechiae 31 occasional (7.5%) HP:0000967
4 bruising susceptibility 31 occasional (7.5%) HP:0000978
5 skin rash 31 frequent (33%) HP:0000988
6 pruritus 31 frequent (33%) HP:0000989
7 lethargy 31 occasional (7.5%) HP:0001254
8 cerebral hemorrhage 31 occasional (7.5%) HP:0001342
9 ascites 31 occasional (7.5%) HP:0001541
10 thrombocytopenia 31 occasional (7.5%) HP:0001873
11 leukopenia 31 occasional (7.5%) HP:0001882
12 fever 31 hallmark (90%) HP:0001945
13 diarrhea 31 occasional (7.5%) HP:0002014
14 nausea and vomiting 31 occasional (7.5%) HP:0002017
15 abdominal pain 31 frequent (33%) HP:0002027
16 gastrointestinal hemorrhage 31 occasional (7.5%) HP:0002239
17 hepatomegaly 31 occasional (7.5%) HP:0002240
18 headache 31 hallmark (90%) HP:0002315
19 hypotension 31 occasional (7.5%) HP:0002615
20 arthralgia 31 frequent (33%) HP:0002829
21 hypoproteinemia 31 occasional (7.5%) HP:0003075
22 cardiorespiratory arrest 31 occasional (7.5%) HP:0006543

UMLS symptoms related to Dengue Disease:


pruritus, fever

MGI Mouse Phenotypes related to Dengue Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 FCGR1A ICAM1 MBL2 PIK3C2A PTPN11 RAF1
2 immune system MP:0005387 9.32 CD40LG FCGR1A ICAM1 MBL2 PIK3C2A PTPN11
Sources

Drugs & Therapeutics for Dengue Disease

About this section

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 46936176 6474909
12 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
13 Antiparasitic Agents Phase 2, Phase 3,Phase 1,Not Applicable
14 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable
15 DEET Phase 3
16 Insect Repellents Phase 3
17 Protective Agents Phase 3
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
19
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
20
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
21
Ribavirin Approved Phase 2 36791-04-5 37542
22
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
23 Analgesics Phase 1, Phase 2,Not Applicable
24 Analgesics, Non-Narcotic Phase 1, Phase 2,Not Applicable
25 Anthelmintics Phase 1, Phase 2
26 Anti-Inflammatory Agents Phase 1, Phase 2,Not Applicable
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2,Not Applicable
28 Antimalarials Phase 1, Phase 2,Not Applicable
29 Antiprotozoal Agents Phase 1, Phase 2,Not Applicable
30 Antirheumatic Agents Phase 1, Phase 2,Not Applicable
31 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
32 Peripheral Nervous System Agents Phase 1, Phase 2,Not Applicable
33 Antimetabolites Phase 2
34 Antiviral Agents Phase 2
35 Cortisol succinate Phase 2
36 Hydrocortisone 17-butyrate 21-propionate Phase 2
37 Hydrocortisone acetate Phase 2
38 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
39 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
40 Coagulants Phase 2
41 Hemostatics Phase 2
42
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
43
Aluminum sulfate Approved Phase 1 10043-01-3
44 Papaya Approved, Nutraceutical Phase 1
45 Adjuvants, Immunologic Phase 1
46 Antacids Phase 1
47 Anti-Ulcer Agents Phase 1
48 Gastrointestinal Agents Phase 1
49
Acetaminophen Approved Not Applicable 103-90-2 1983
50
Artesunate Approved, Investigational Not Applicable 88495-63-0 5464098 6917864

Interventional clinical trials:

(show top 50) (show all 169)

# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
4 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
5 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
6 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
7 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
8 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
9 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
10 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
11 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
12 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Recruiting NCT03341637 Phase 3
13 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
14 Study of INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS) Recruiting NCT03037164 Phase 3
15 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
16 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
17 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
18 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
19 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Active, not recruiting NCT03423173 Phase 3
20 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
21 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
22 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
23 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
24 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
25 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
26 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
27 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
28 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
29 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
30 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
31 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
32 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
33 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
34 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
35 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
36 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
37 Study of Febrile Illness for Dengue-Endemic Areas in Latin America Completed NCT01293331 Phase 1, Phase 2
38 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
39 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00239577 Phase 2
40 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
41 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
42 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
43 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
44 A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed NCT00350337 Phase 2
45 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
46 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand Completed NCT00370682 Phase 2
47 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
48 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
49 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Completed NCT01943305 Phase 2
50 Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand Recruiting NCT02332733 Phase 2

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Sources

Genetic Tests for Dengue Disease

About this section
Sources

Anatomical Context for Dengue Disease

About this section

MalaCards organs/tissues related to Dengue Disease:

38
Skin, Eye, Testes, Bone, Heart, Thyroid, T Cells
Sources

Publications for Dengue Disease

About this section

Articles related to Dengue Disease:

(show top 50) (show all 254)
# Title Authors Year
1
Spatial-Temporal Analysis of Dengue Fever and Hemorrhagic Fever in Mexico from 1995-2015. ( 29402463 )
2018
2
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
3
Epidemiological Characteristics of Dengue Disease in Latin America and in the Caribbean: A Systematic Review of the Literature. ( 28392806 )
2017
4
Modeling Impact of Temperature and Human Movement on the Persistence of Dengue Disease. ( 29312458 )
2017
5
Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array. ( 28242509 )
2017
6
Dual infection with Japanese encephalitis and dengue fever: Issues with diagnosis. ( 28084252 )
2017
7
Dengue fever triggering hemiconvulsion hemiplegia epilepsy in a child. ( 28488637 )
2017
8
Optical coherence tomography angiography features of acute macular neuroretinopathy in dengue fever. ( 29133664 )
2017
9
Trends of Dengue Disease Epidemiology. ( 28579763 )
2017
10
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
11
Cardiac tamponade in a patient with severe dengue fever. ( 29160522 )
2017
12
Bayesian dynamic modeling of time series of dengue disease case counts. ( 28671941 )
2017
13
Dengue fever presenting as cauda equina syndrome. ( 28739570 )
2017
14
Myelitis and cauda equina involvement following dengue fever. A case report and review of the literature. ( 29294422 )
2017
15
Epidemiological characteristics of dengue disease in Saurashtra region, India, during year 2015. ( 29302526 )
2017
16
Pattern Of Presentation Among Adults Hospitalized With Dengue Disease. ( 29076677 )
2017
17
Relative risk estimation of dengue disease at small spatial scale. ( 28810908 )
2017
18
Potential Risk Areas of Aedes albopictus in South-Eastern Iran: A Vector of Dengue Fever, Zika, and Chikungunya. ( 28928720 )
2017
19
Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. ( 28659489 )
2017
20
Effect of Rainfall for the Dynamical Transmission Model of the Dengue Disease in Thailand. ( 28928793 )
2017
21
Antibody-dependent enhancement of severe dengue disease in humans. ( 29097492 )
2017
22
Correlation of altered expression of a long non-coding RNA, NEAT1, in peripheral blood mononuclear cells with dengue disease progression. ( 29031635 )
2017
23
Hypokalemia in dengue fever- A descriptive study. ( 27727941 )
2016
24
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. ( 27532617 )
2016
25
Dengue fever with diffuse cerebral hemorrhages, subdural hematoma and cranial diabetes insipidus. ( 27165581 )
2016
26
Early diagnosis of dengue disease severity in a resource-limited Asian country. ( 27670906 )
2016
27
A rare case of an 8-month-old child with dengue fever complicated by acute diffuse transverse myelitis. ( 27857814 )
2016
28
High prevalence of clinically unsuspected dengue disease among children in Ribeirao Preto City, Brazil. ( 27004990 )
2016
29
Acute acalculous cholecystitis as initial manifestation in dengue fever. ( 27728380 )
2016
30
A case of acalculous cholecystitis in the course of dengue fever in a traveller returned from Brazil. ( 27029928 )
2016
31
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. ( 27506852 )
2016
32
Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. ( 27180198 )
2016
33
Effect of temperature, relative humidity and rainfall on dengue fever and leptospirosis infections in Manila, the Philippines. ( 27608858 )
2016
34
Isolated unilateral sixth cranial nerve palsy: A rare presentation of dengue fever. ( 28461846 )
2016
35
Co-infection of dengue fever and hepatitis A in a Russian traveler. ( 27516967 )
2016
36
Acute Posterior Multifocal Placoid Pigment Epitheliopathy Following Dengue Fever: A New Association for an Old Disease. ( 26902823 )
2016
37
Unusual Presentation of Dengue Fever: A child with acute myocarditis. ( 26909198 )
2016
38
Dengue Disease Modelling and Forecasting: Utility and Limitations. ( 27292001 )
2016
39
Seasonal Distribution and Climatic Correlates of Dengue Disease in Dhaka, Bangladesh. ( 27114293 )
2016
40
Clinical and laboratory signs associated to severe dengue disease in hospitalized children. ( 27112034 )
2016
41
Guillain-BarrAc syndrome and dengue fever: report on ten new cases in Brazil. ( 27992005 )
2016
42
Anterior ischemic optic neuropathy following dengue fever. ( 27843231 )
2016
43
Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice. ( 27341339 )
2016
44
Stuck with pancytopenia in dengue fever: Evoke for hemophagocytic syndrome. ( 26955219 )
2016
45
Central retinal vein occlusion concomitant with dengue fever. ( 27847619 )
2016
46
Dengue fever associated with extreme reactive thrombocytosis ( 28078838 )
2016
47
Dengue Fever Presenting Atypically with Viral Conjunctivitis and Subacute Thyroiditis. ( 27376214 )
2016
48
High degree atrioventricular block with ventricular asystole in a case of dengue fever. ( 27751287 )
2016
49
Dengue Fever-Associated Maculopathy and Panuveitis in Australia. ( 28078150 )
2016
50
Transverse Myelitis as an Unusual Complication of Dengue Fever. ( 27956656 )
2016
Sources

Variations for Dengue Disease

About this section
Sources

Expression for Dengue Disease

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55kDa Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript (non-protein coding) Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3, skin-derived Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex, subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein-like 3 Blood - 3.72 0.000
27 TOP2A topoisomerase (DNA) II alpha Blood + 3.71 0.000
28 NOV nephroblastoma overexpressed Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.62 0.000
32 KIAA0101 KIAA0101 Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1, soluble Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM abnormal spindle microtubule assembly Blood + 3.52 0.000
42 OR2W3 olfactory receptor, family 2, subfamily W, member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 (Psf2 homolog) Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.
Sources

Pathways for Dengue Disease

About this section

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 62
Show member pathways
 13.86 CCL5 CD209 CD40LG FCGR1A ICAM1 IL11
2
Class I MHC mediated antigen processing and presentation 62
Show member pathways
 13.25 CD209 CD40LG FCGR1A ICAM1 PTPN11 RAF1
3
Cytokine Signaling in Immune system 62
Show member pathways
 12.97 CCL5 CD40LG FCGR1A ICAM1 IL11 PTPN11
4
Interferon gamma signaling 62
Show member pathways
 12.37 FCGR1A ICAM1 PTPN11 VCAM1
5
Development VEGF signaling via VEGFR2 - generic cascades 21
Show member pathways
 12.18 ICAM1 PTPN11 RAF1 VCAM1
6
Jak-STAT signaling pathway (KEGG) 36
Show member pathways
 12.09 IL11 PTPN11 RAF1 THPO
7
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.9 IL11 THPO VCAM1
8
Influenza A 36
Show member pathways
 11.86 CCL5 CD209 HCFC1 ICAM1 IVNS1ABP PTPN11
9
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 61
11.84 CD209 IL11 THPO
10
TNF signaling pathway 36
11.79 CCL5 ICAM1 VCAM1
11
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 62
11.75 CD40LG FCGR1A ICAM1 VCAM1
12
Hematopoietic cell lineage 36
11.72 FCGR1A IL11 THPO
13
NF-kappa B signaling pathway 36
11.7 CD40LG ICAM1 VCAM1
14
Rheumatoid arthritis 36
11.67 CCL5 ICAM1 IL11
15
IgA-Producing B Cells in the Intestine 61
11.47 CD40LG ICAM1 VCAM1
16
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.43 CD40LG ICAM1 VCAM1
17
Staphylococcus aureus infection 36
11.36 FCGR1A ICAM1 MBL2
18
Malaria 36
11.23 CD40LG ICAM1 VCAM1
19
Immune response_Role of integrins in NK cells cytotoxicity 21
11.1 ICAM1 PTPN11 RAF1 VCAM1
20
CD209 (DC-SIGN) signaling 62
10.95 CD209 RAF1
21
Interleukin-11 Signaling Pathway 1
10.9 ICAM1 IL11 PTPN11 RAF1
22
G-protein signaling_Rap2B regulation pathway 21
10.81 CCL5 CD40LG IL11 RAF1 THPO
23
LDL Oxidation in Atherogenesis 60
10.8 ICAM1 VCAM1
Sources

GO Terms for Dengue Disease

About this section

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL5 CD40LG ICAM1 IL11 MBL2 THPO
2 cell surface GO:0009986 9.35 CD209 CD40LG ICAM1 MBL2 VCAM1
3 external side of plasma membrane GO:0009897 8.92 CD209 CD40LG ICAM1 VCAM1

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.8 CD209 HCFC1 ICAM1 IVNS1ABP VCAM1
2 cellular response to tumor necrosis factor GO:0071356 9.71 CCL5 ICAM1 VCAM1
3 platelet activation GO:0030168 9.7 CD40LG PTPN11 RAF1
4 regulation of immune response GO:0050776 9.67 CD40LG FCGR1A ICAM1 VCAM1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.63 FCGR1A ICAM1 VCAM1
6 B cell differentiation GO:0030183 9.61 CD40LG IL11 VCAM1
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 CCL5 ICAM1 PTPN11 RAF1 THPO
8 regulation of protein complex assembly GO:0043254 9.51 HCFC1 PTPN11
9 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.5 CD209 ICAM1 VCAM1
10 neurotrophin TRK receptor signaling pathway GO:0048011 9.49 PTPN11 RAF1
11 negative regulation of hormone secretion GO:0046888 9.48 IL11 PTPN11
12 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
13 positive regulation of T cell proliferation GO:0042102 9.26 CCL5 CD209 CD40LG VCAM1
14 leukocyte cell-cell adhesion GO:0007159 9.02 CCL5 CD209 CD40LG ICAM1 VCAM1

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mannose binding GO:0005537 8.96 CD209 MBL2
2 cytokine activity GO:0005125 8.92 CCL5 CD40LG IL11 THPO
Sources

Sources for Dengue Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....